Acute non-cardioembolic ischemic stroke

- Participant must be 45 years of age and older at the time of signing the informed consent
- Non-cardioembolic ischemic stroke with
 -- persistent signs and symptoms of stroke lasting for ≥ 24 hours OR
 -- acute brain infarction documented by computed tomography (CT) or MRI AND
 -- with the intention to be treated with antiplatelet therapy during the study conduct
- Imaging of brain (CT or MRI) ruling out hemorrhagic stroke or another pathology that could explain symptoms (e.g. brain tumor, abscess, vascular malformation)
- Severity of index event nearest the time of randomization:
 -- Part A: minor stroke (defined as National Institutes of Health Stroke Scale (NIHSS) ≤ 7) can be enrolled
 -- Part B: participants with minor or moderate stroke and NIHSS ≤ 15 can be enrolled. Participants undergoing thrombolysis or endovascular therapy (mechanical thrombectomy) can be enrolled but at the earliest 24 hours after the intervention
- Randomization within 48 hours after the onset of symptoms of the index event (or after patients were last known to be without symptoms in case of wake-up stroke)
- Ability to conduct an MRI either before randomization or within 72 hours after randomization

- Prior ischemic stroke within last 30 days of index event
- History of atrial fibrillation or suspicion of cardioembolic source of stroke
- Dysphagia with inability to safely swallow study medication
- Contraindication to perform brain MRI
- Part A only: thrombolysis or endovascular therapy (mechanical thrombectomy) performed for index event
- Active bleeding; known bleeding disorder, history of major bleeding (intracranial, retroperitoneal, intraocular) or clinically significant gastrointestinal bleeding within last 6 months of randomization.